• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

For Industry

  • Print
  • Share
  • E-mail

Public Meeting on Fibromyalgia Patient-Focused Drug Development


On  March 26, 2014, FDA conducted a public meeting on Patient-Focused Drug Development for fibromyalgia. FDA is interested in obtaining patient input on the impact of fibromyalgia on daily life and patients’ views on currently available therapies to treat the condition. This is a rescheduling of the original December 10, 2013 meeting.

Date: March 26, 2014 
Time: 1:00 p.m. to 5:00 p.m. 
Location:FDA White Oak Campus
10903 New Hampshire Ave.
Building 31, Room 1503 B and C (Great Room)
Silver Spring, MD 20993
(Information about arrival to FDA’s White Oak campus)  
Registration: 
To register for this meeting, visit: https://marchfibromyalgia.eventbrite.com.
Registration closed on March 20, 2014.

Submitting comments to the docket: In addition to providing input at the public meeting, patient stakeholders are invited to provide their perspectives on the discussion questions through the public docket. The docket closes on May 26, 2014.

 

Webcast Recording